Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Duke University
This protocol requires radiation treatments to be performed with a stereotactic technique with the use of a 3-D coordinate system defined by implanted transponders (i.e. Calypso) or use of the ExacTrac system and/or use cone-beam CT (CBCT) with fiducial markers.
Age
40–82
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Histologically confirmed diagnosis of adenocarcinoma of the prostate within 365 days of study enrollment
History/physical examination with digital rectal examination of the prostate within 8 weeks prior to study enrollment
Gleason score less than or equal to 7
Clinical Stage T1-T2c
PSA
less than or = 15 ng/ml prior to start of therapy if Gleason \< or = 6 or
less than or = 10 ng/ml prior to start of therapy if Gleason = 7
Zubrod Performance Status 0-1
Age \> 40
You may not be if
Prior or concurrent invasive malignancy (except non-melanomatous skin cancer) or lymphomatous/hematogenous malignancy unless continually disease free for a minimum of 5 years. (Carcinoma in situ of the bladder or oral cavity is permissible)
Evidence of distant metastases
Regional lymph node involvement
Significant urinary obstruction
Estimated prostate gland \> 100 grams
Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Previous hormonal therapy, such as LHRH agonists (e.g. goserelin, leuprolide), anti-androgens (e.g., flutamide, bicalutamide), estrogens (e.g., DES), or surgical castration (bilateral orchiectomy) or planned concurrent androgen deprivation therapy
Previous or concurrent cytotoxic chemotherapy for prostate cancer
Prosthetic implants in the pelvic region that contain metal or conductive materials (e.g., an artificial hip).
Severe, active comorbidity
Clareo Health | Stereotactic Body Radiotherapy (SBRT) for Prostate Cancer
